Diagnosis & Disease Information

XALKORI® (crizotinib) for Locally Advanced or Metastatic ALK+ NSCLC

This slideshow reviews drug information for XALKORI® (crizotinib), indicated for locally advanced or metastatic ALK+NSCLC. Table of Contents Slide 3: Indication, Dosage, and AdministrationSlide 8: Use in Specific PopulationsSlide 10: Clinical PharmacologySlide 15: Warnings and PrecautionsSlide 19: Clinical Safety and EfficacySlide 27: Drug Storage and Supply Slide 29: References

Next post in Lung Cancer